IVVD
Invivyd, Inc.
1.57
USD
This page is just a preview of the data found in TrendSpider’s full version
Invivyd, Inc. stock is up 3.29% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November.
Adagio Therapeutics focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.
